Expertise in
19
conditions

Dr. Fredric G. Regenstein

Hepatology
Administrators Of The Tulane Educational Fund
1415 Tulane Ave, 
New Orleans, LA 
Accepting New Patients
Expertise in
19
conditions
Administrators Of The Tulane Educational Fund
1415 Tulane Ave, 
New Orleans, LA 
OverviewInsuranceLocationsClinical ResearchSimilar Doctors

Overview

Fredric Regenstein is a Hepatologist in New Orleans, Louisiana. Dr. Regenstein is highly rated in 19 conditions, according to our data. His top areas of expertise are Visceromegaly, Hepatitis, Cirrhosis, Enlarged Liver, and Liver Transplant. Dr. Regenstein is currently accepting new patients.

His clinical research consists of co-authoring 6 peer reviewed articles and participating in 6 clinical trials. MediFind looks at clinical research from the past 15 years.

Specialties
Hepatology
Licenses
Internal Medicine in LA
Hospital Affiliations
East Jefferson General Hospital
St Tammany Parish Hospital
Ochsner Medical Center Acute
Memorial Hospital At Gulfport
Languages Spoken
English
Gender
Male

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Accepted insurance plans:

Aetna
  • EPO
  • HMO
  • POS
  • PPO
Anthem
  • EPO
  • HMO
  • POS
  • PPO
Blue Cross Blue Shield
  • EPO
  • HMO
  • POS
  • PPO
Change Healthcare
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
Cigna
  • EPO
  • HMO
  • PPO
Health Care Services Corporation
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • OTHER COMMERCIAL
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
  • PPO
Humana
  • HMO
  • INDEMNITY
  • POS
  • PPO
Louisiana Healthcare Connections
  • HMO
  • MANAGED MEDICAID PLAN
Managed Medicaid
  • OTHER MANAGED MEDICAID
Medicaid
  • OTHER MEDICAID
  • STATE MEDICAID
UnitedHealthcare
  • EPO
  • HMO
  • POS
  • PPO
Walgreens
  • MEDICARE DISCOUNT CARD
  • MEDICARE PDP
  • OTHER MEDICARE
Wellcare
  • EPO
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
View 8 Less Insurance Carriers -

Locations

ADMINISTRATORS OF THE TULANE EDUCATIONAL FUND
1415 Tulane Ave, New Orleans, LA 70112

Additional Areas of Focus

Dr. Regenstein has provided the following conditions as areas of focus. Please note that we may not have enough data to validate their experience in some of these conditions.

Non-Alcoholic Fatty Liver Disease
Nonalcoholic Steatohepatitis (NASH)

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

6 Clinical Trials

A Seamless, Adaptive, Phase 2b/3, Double-Blind, Randomized, Placebo-controlled, Multicenter, International Study Evaluating the Efficacy and Safety of Belapectin (GR MD-02) for the Prevention of Esophageal Varices in NASH Cirrhosis
A Seamless, Adaptive, Phase 2b/3, Double-Blind, Randomized, Placebo-controlled, Multicenter, International Study Evaluating the Efficacy and Safety of Belapectin (GR MD-02) for the Prevention of Esophageal Varices in NASH Cirrhosis
Enrollment Status: Active_not_recruiting
Publish Date: April 11, 2025
Intervention Type: Drug
Study Drug: Belapectin
Study Phase: Phase 2/Phase 3
A Phase 3, Double-Blind, Randomized, Long-Term, Placebo-Controlled, Multicenter Study Evaluating the Safety and Efficacy of Obeticholic Acid in Subjects With Nonalcoholic Steatohepatitis
A Phase 3, Double-Blind, Randomized, Long-Term, Placebo-Controlled, Multicenter Study Evaluating the Safety and Efficacy of Obeticholic Acid in Subjects With Nonalcoholic Steatohepatitis
Enrollment Status: Terminated
Publish Date: October 01, 2024
Intervention Type: Drug
Study Drug: Obeticholic Acid
Study Phase: Phase 3
A Phase 4, Double-Blind, Randomized, Placebo-Controlled, Multicenter Study Evaluating the Effect of Obeticholic Acid on Clinical Outcomes in Patients With Primary Biliary Cholangitis
A Phase 4, Double-Blind, Randomized, Placebo-Controlled, Multicenter Study Evaluating the Effect of Obeticholic Acid on Clinical Outcomes in Patients With Primary Biliary Cholangitis
Enrollment Status: Terminated
Publish Date: March 09, 2023
Intervention Type: Drug
Study Drug: Obeticholic Acid 
Study Phase: Phase 4
A Phase 3 Randomized, Open-Label Study Comparing Pexa Vec (Vaccinia GM CSF / Thymidine Kinase-Deactivated Virus) Followed by Sorafenib Versus Sorafenib in Patients With Advanced Hepatocellular Carcinoma (HCC) Without Prior Systemic Therapy
A Phase 3 Randomized, Open-Label Study Comparing Pexa Vec (Vaccinia GM CSF / Thymidine Kinase-Deactivated Virus) Followed by Sorafenib Versus Sorafenib in Patients With Advanced Hepatocellular Carcinoma (HCC) Without Prior Systemic Therapy
Enrollment Status: Completed
Publish Date: December 16, 2020
Intervention Type: Drug, Biological
Study Phase: Phase 3
A Randomized, Double-Blind, Placebo-Controlled, Proof-of-Concept Study Evaluating the Efficacy and Safety of Baricitinib (LY3009104) in Patients With Primary Biliary Cholangitis Who Have an Inadequate Response or Are Intolerant to UDCA
A Randomized, Double-Blind, Placebo-Controlled, Proof-of-Concept Study Evaluating the Efficacy and Safety of Baricitinib (LY3009104) in Patients With Primary Biliary Cholangitis Who Have an Inadequate Response or Are Intolerant to UDCA
Enrollment Status: Terminated
Publish Date: October 14, 2020
Intervention Type: Drug
Study Phase: Phase 2
A Phase 2 Double-blind, Randomized, Placebo-controlled, Dose-finding Study to Evaluate the Safety, Tolerability and Efficacy of Volixibat Potassium, an Apical Sodium-Dependent Bile Acid Transporter Inhibitor (ASBTi) in Adults With Nonalcoholic Steatohepatitis (NASH)
A Phase 2 Double-blind, Randomized, Placebo-controlled, Dose-finding Study to Evaluate the Safety, Tolerability and Efficacy of Volixibat Potassium, an Apical Sodium-Dependent Bile Acid Transporter Inhibitor (ASBTi) in Adults With Nonalcoholic Steatohepatitis (NASH)
Enrollment Status: Terminated
Publish Date: November 25, 2019
Intervention Type: Drug
Study Phase: Phase 2
View 5 Less Clinical Trials

6 Total Publications

Light Chain Deposition Disease: An Unusual Cause of Portal Hypertension.
Light Chain Deposition Disease: An Unusual Cause of Portal Hypertension.
Journal: Hepatology (Baltimore, Md.)
Published: November 04, 2020
Similar Doctors
Expertise in
25
conditions
Dr. George P. Therapondos
Hepatology
Expertise in
25
conditions
Dr. George P. Therapondos
Hepatology

Ochsner Clinic LLC

1514 Jefferson Hwy, 
New Orleans, LA 
 (4.2 mi)
504-842-3000
Languages Spoken:
English
See accepted insurances
Accepting New Patients
Offers Telehealth

George Therapondos is a Hepatologist in New Orleans, Louisiana. Dr. Therapondos is highly rated in 25 conditions, according to our data. His top areas of expertise are Hepatitis, Hepatitis C, Cirrhosis, Liver Transplant, and Endoscopy. Dr. Therapondos is currently accepting new patients.

Expertise in
19
conditions
Dr. Brian B. Borg
Hepatology
Expertise in
19
conditions
Dr. Brian B. Borg
Hepatology

Administrators Of The Tulane Educational Fund

1415 Tulane Ave, 
New Orleans, LA 
 (0.1 mi)
504-988-5110
Languages Spoken:
English, Farsi, French
See accepted insurances
Accepting New Patients

Brian Borg is a Hepatologist in New Orleans, Louisiana. Dr. Borg is highly rated in 19 conditions, according to our data. His top areas of expertise are Nonalcoholic Steatohepatitis (NASH), Primary Biliary Cholangitis, Cirrhosis, Liver Transplant, and Colonoscopy. Dr. Borg is currently accepting new patients.

Expertise in
19
conditions
Dr. Hrishikesh V. Samant
Hepatology
Expertise in
19
conditions
Dr. Hrishikesh V. Samant
Hepatology

Ochsner Clinic LLC

1514 Jefferson Hwy, 
New Orleans, LA 
 (4.2 mi)
504-842-3000
Languages Spoken:
English
See accepted insurances
Accepting New Patients
Offers Telehealth

Hrishikesh Samant is a Hepatologist in New Orleans, Louisiana. Dr. Samant is highly rated in 19 conditions, according to our data. His top areas of expertise are Liver Failure, Portal Hypertension, Cirrhosis, Liver Transplant, and Endoscopy. Dr. Samant is currently accepting new patients.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Regenstein's expertise for a condition
ConditionClose
    View All 15 Advanced Conditions
    View All 9 Experienced Conditions
    Want to save this doctor for later?
    Sign Up
    Is this your doctor?
    Find A Second Opinion
    Not sure about your diagnosis?
    Check Your Symptoms
     
     
     
     
    Learn about our expert tiers
    Learn More
    Are you the provider on this profile?
    Claim Profile